The company's stock could top $100 within a year, climbing by a third. Abercrombie's new Gilly Hicks lingerie chain looks promising, joining the hugely popular Hollister.

Celgene's earnings-growth pace could keep rising -- to 50% -- on more drug triumphs, as could the high (some say too high) 24 multiple on its stock. But at 54 now, it may be worth 20% more.

If Zurich Financial Services stays on course to deliver strong earnings and high returns on equity, its shares, now 317 Swiss francs, could rally 25% or more.

Marvell shares could double in two years if it fixes its options mess, controls costs and gets a 3G-capable chip to market.

For the price of a Disney share, too, an investor effectively buys access to a braintrust probably unrivaled in American business. Apple's Steve Jobs, a Pixar founder, is Disney's largest shareholder, with 7% of the float. Fellow owner Warren Buffett no doubt picks up the phone for Iger. Procter & Gamble's former CEO, John Pepper, with all the consumer-product knowledge one could want, chairs Disney's board.

We're neutral now, and think investors should cover their short positions and take a walk. The stock sells today for only nine times analysts' '08 earnings estimate of around $2.70 a share, and the shoes are still the rage among soccer moms and nurses, suggesting the stock might not drop much lower from here, at least in the near term.

In her estimation, Wyeth's stock price suggests that investors do not appreciate the value of these assets. At $40, Rubin contends, investors are effectively "getting the pipeline for free." Her analysis suggests that Wyeth's vaccines, biologics (biotechnology drugs) and OTC assets are worth about $35, or about 90% of the stock price. By 2012, Rubin expects biologics and vaccines to account for about 70% of Wyeth's earnings. She raised her investment rating on the stock to Overweight from Equal Weight, and upped her one-year price target to $48 from $46.